SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 654.74-0.5%Nov 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (3021)6/29/2020 3:32:39 PM
From: Biotechwantabe  Read Replies (1) of 3557
 
Regeneron Pharmaceuticals, Inc USAProduct Name: SarilumabDescription:
Kevzara (sarilumab) is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor

Unique Impact:
Conducted under the existing BARDA Regeneron OTA collaboration, a U.S. Phase 2/3 clinical trial will help determine if Kevzara can be used to reduce symptoms of inflammation in hospitalized people with critical or severe COVID-19

Status: Phase 2/3

Base Award Amount: $16,368,388 (March 19, 2020)
Mod/Option 1 Amount: $53,517,946 (June 17, 2020)

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News